Jason O'Byrne - Feb 22, 2025 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Stock symbol
VIR
Transactions as of
Feb 22, 2025
Transactions value $
$0
Form type
4
Date filed
2/25/2025, 03:41 PM
Previous filing
Nov 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +40K +53.33% $0.00 115K Feb 22, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +80K $0.00 80K Feb 22, 2025 Common Stock 80K $9.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remaining shares vest in 36 equal monthly installments thereafter.